Johnson & Johnson disclosed promising early data from its dual CD19/CD20-targeting CAR-T program in relapsed/refractory large B-cell lymphoma. Among patients with one prior therapy, objective response rate hit 100%, with 80% showing no detectable disease. Patients with two or more prior treatments had 92% response and 75% complete remission rates. Safety data revealed manageable adverse events. These findings, presented at EHA 2025, signify important progress in improving durable outcomes over single-antigen CAR-T therapies.